Aslan Pharmaceuticals Ltd Adr (ASLN) has released an update.
ASLAN Pharmaceuticals has reported progress across its clinical pipeline, notably positive results from its TREK-AD Phase 2b study for eblasakimab in atopic dermatitis and a promising Phase 2 trial for farudodstat in alopecia areata, with topline data expected in Q3 2024. The company has also secured a favorable opinion from the European Patent Office, potentially extending farudodstat’s patent protection until 2043, and reported encouraging safety profiles and efficacy data for eblasakimab in treating COPD. Financially, ASLAN managed to reduce its cash burn for 2024 with strategic prepayments on its loan agreement.
For further insights into ASLN stock, check out TipRanks’ Stock Analysis page.